The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in Isfahan, Iran

Review of Diabetic Studies

Volumn 4, Issue 4, 2007, Pages 242-248

  Amini, Massoud ^a   Safaei, Hassan ^a   Aminorroaya, Ashraf ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic nephropathy; Incidence; Microalbuminuria; Risk factor; Type 2 diabetes

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INCIDENCE; IRAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; URINARY EXCRETION; URINE LEVEL;

EID: 67649252692     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2007.4.242     Document Type: Article

References (40)

1. Vanrenterghem Y, Jones EH. Report on management of renale failure in Europe, XXVI, 1995. Report based on the Centre Questionnaire, 1995. The ERA-EDTA Registry. Nephrol Dial Transplant 1996. 11(Suppl 7):28-32.
2. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999. 34:795-808. (Pubitemid 29521694)
3. Raine AE. Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetic patients in Europe. Diabetologia 1993. 36:1099-1104. (Pubitemid 23288782)
4. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002. 346:1145-1151.
5. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996. 335(22):1636-1642. (Pubitemid 26392728)
6. Remuzzi G, Schiepatti A, Ruggementi P. Nephropathy in patients with type 2 diabetes. New Engl J Med 2002. 342:1145-1151. (Pubitemid 34984606)
7. Parving HH, Chaturvedi N, Viberti G, Mogensen CE. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2002. 25:406-407.
8. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984. 310:356-360. (Pubitemid 14179541)
9. World Health Organization. Obesity: preventing and managing the global epidemic. Report of consultation obesity. Geneva, 1998.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003. 42:1206-1252. (Pubitemid 37553153)
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972. 18:499-502.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001. 285(19):2486-2497.
13. Haffner SM, American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003. 26(Suppl 1):S83-S86. (Pubitemid 36928964)
14. World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Geneva, 1998.
15. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU. Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 1998. 21:530-534. (Pubitemid 28172929)
16. John L, Rao PS, Kanagasabapathy AS. Rate of progression of albuminuria in type II diabetes. Five-year prospective study from south India. Diabetes Care 1994. 17(8):888-890. (Pubitemid 24235513)
17. Nelson RG, Knowler WC, Pettitt DJ, Hanson RL, Bennett PH. Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM. Diabetes Care 1995. 18:182-187.
18. Bruno G, Cavallo-Perin P, Bargero G, Borra M, Calvi V, D'Errico N, Deambrogio P, Pagano G. Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care 1996. 19:43-47. (Pubitemid 26006613)
19. Dasmahapatra A, Bale A, Raghuwanshi MP, Reddi A, Byrne W, Suarez S, Nash F, Varagiannis E, Skurnick JH. Incipient and overt diabetic nephropathy in African Americans with NIDDM. Diabetes Care 1994. 17(4):297-304. (Pubitemid 24123410)
20. Oue T, Namba M, Nakajima H, Ono A, Horikawa Y, Yamamoto K, Hamaguchi T, Fujino-Kurihara H, Yamasaki T, Tomita K, Miyagawa J, Hanafusa T, Matsuzawa Y. Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients - a 10 year follow-up study. Diabetes Res Clin Pract 1999. 46:47-55. (Pubitemid 29475002)
21. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003. 63:225-232. (Pubitemid 35463925)
22. Torffvit O, Agardh E, Agardh CD. Albuminuria and associated medical risk factors: a cross-sectional study in 451 type II (noninsulin-dependent) diabetic patients. Part 2. J Diabet Complications 1991. 5(1):29-34.
23. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992. 15:815-819.
24. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997. 314:783. (Pubitemid 27117048)
25. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995. 47(6):1703-1720.
26. Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, Nuttall FQ, Sawin CT, Comstock JP, Silbert CK. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000. 23:1478-1485.
27. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000. 321:405-412. (Pubitemid 30609442)
28. Forsblom CM, Groop PH, Ekstrand A, Totterman KJ, Sane T, Saloranta C, Groop L. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998. 21:1932-1938. (Pubitemid 28478296)
29. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995. 44(11):1303-1309.
30. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995. 18:258-268.
31. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998. 158:998-1004. (Pubitemid 28213577)
32. Schmitz A, Vaeth M, Mogensen CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994. 37:1251-1258. (Pubitemid 24356765)
33. Haneda M, Kikkawa R, Togawa M, Koya D, Kajiwara N, Uzu T, Shigeta Y. High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1992. 6(3):181-185. (Pubitemid 23129151)
34. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998. 317(7160):703-713. (Pubitemid 28414300)
35. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998. 317(7160):713-720. (Pubitemid 28414301)
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993. 329:1456-1462.
37. Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. Am J Soc Nephrol 2002. 13:S224-S229. (Pubitemid 35216029)
38. Cruickshanks KJ, Ritter LL, Klein R, Moss SE. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993. 100:862-867. (Pubitemid 23163496)
39. Agardh CD, Agardh E, Torffvit O. The prognostic value of albuminuria for the development of cardiovascular disease and retinopathy: a 5-year follow-up of 451 patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1996. 32(1-2):35-44. (Pubitemid 126334423)
40. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996. 19:1243-1248. (Pubitemid 26363440)